Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

OraSure Technologies InteliSwab™ COVID-19 Rapid Test Pro Kit Controls

External quality control reagents to monitor the performance of InteliSwab™ COVID-19 rapid test pro with direct anterior nasal samples

Supplier:  OraSure Technologies 10010613

Catalog No. 23-222-114


Add to Cart

Description

Description

  • For use only with InteliSwab™ COVID-19 Rapid Test Pro
  • Kit control box contains:
    • Instructions for use (IFU)
    • Specimen collection loops
    • Two vials:
      • One COVID-19 positive control
      • One COVID-19 negative control
Specifications

Specifications

36°F to 46°F
InteliSwab™ COVID-19 Rapid Test Pro
Instructions for use, Specimen collection loops, COVID-19 positive control, COVID-19 negative control
SARS-CoV-2 Nucleocapsid protein antigen
InteliSwab™ Kit Controls
SDS
Documents

Documents

Product Certifications
Promotions

Promotions

Provide Content Correction

We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Cancel Submit

This product has not been FDA cleared or approved, but has been authorized by FDA under an EUA for use by authorized laboratories. This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.